20 articles
New peptide delivery system restores brain connections and memory function in Alzheimer's models, offering hope for treating cognitive decline.
New review reveals how engineered peptides could revolutionize Alzheimer's therapy by targeting multiple disease pathways simultaneously.
DPCPX treatment enhanced neurogenesis and improved motor/memory function in stroke recovery studies using advanced PET imaging.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
Researchers discover a phospholipid derivative that protects brain cells by calming overactive immune cells in dementia-prone mice.
A newly identified proteasome activator, PA200, clears toxic alpha-synuclein aggregates and maintains function even when standard protein-disposal systems fail.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
Losing a key cholinergic peptide dramatically worsens memory in Alzheimer's mice, pointing to a overlooked pathway in cognitive decline.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Synthetic peptide chimeras degrade amyloid-beta across the blood-brain barrier, improving cognition in mice with fewer risks than current immunotherapies.
Blocking the protein PTP1B boosted memory and cleared brain plaque in mice, with potential links to diabetes and obesity treatment.
Boosting BNIP3 in muscle tissue extends fly lifespan and shields the brain from age-related degeneration via a muscle-brain signaling axis.
Stanford researchers find pioglitazone and liraglutide improve CNS insulin signaling, measured via neuron-derived vesicles in blood.
A novel brain organoid stress model reveals how combining walnut peptide and theanine activates BDNF pathways to reduce anxiety and boost cognition.
A deep mechanistic exploration of how hypothalamic IKKΞ²/NF-ΞΊB signaling, htNSC exosomal communication, and multi-axis hormonal dysregulation drive systemic aging β plus cutting-edge therapeutic strategies.
AAV delivery of AIBP protein restores cholesterol balance, silences inflammation, and preserves vision in glaucoma models.
New research reveals how ubiquitin ligase COP1 suppresses brain inflammation by degrading c/EBPΞ² protein in microglia cells.
A novel AΞ²1-10 peptide vaccine conjugated to carrier proteins reduced plaques, neuroinflammation, and memory deficits in an AD mouse model.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
